FDA Failures During Heparin Crisis Drive Congress’ Stronger Drug Safety Push
This article was originally published in The Tan Sheet
Executive Summary
FDA's role in the handling of contaminated-heparin crisis is illustrative of "the best and the worst" of its performance under the administration, said David Nelson, senior investigator for the House Energy and Commerce Committee
You may also be interested in...
Globalization Act’s Drug Safety Provisions Look Harmful For Industry
The FDA Globalization Act could be devastating to the drug industry while not creating the safety improvements that Congress expects, according to former FDA attorneys
Salmonella Problem Stirs Food Safety Bills, Hearing From Energy & Commerce
At an upcoming hearing, House Energy and Commerce Committee leaders will question executives from labs that tested ingredients at the peanut processing facility linked to widespread recalls due to salmonella contamination
Energy And Commerce Changes, But Stupak Keeps Subcommittee Chair
A frequent critic of FDA and the drug industry remains in the House Energy and Commerce Committee leadership, but the drug and dietary supplement industries are preparing to work with different staff at the crucial committee